Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 04:00PM ET
8.08
Dollar change
-0.08
Percentage change
-0.98
%
IndexRUT P/E- EPS (ttm)-1.82 Insider Own20.06% Shs Outstand256.14M Perf Week0.31%
Market Cap2.26B Forward P/E- EPS next Y-0.70 Insider Trans10.39% Shs Float223.70M Perf Month-22.53%
Income-449.64M PEG- EPS next Q-0.34 Inst Own68.48% Short Float22.34% Perf Quarter-42.41%
Sales1.90M P/S1190.01 EPS this Y32.19% Inst Trans-1.91% Short Ratio8.46 Perf Half Y4.80%
Book/sh2.43 P/B3.32 EPS next Y45.38% ROA-53.07% Short Interest49.96M Perf Year-6.48%
Cash/sh1.27 P/C6.35 EPS next 5Y- ROE-66.77% 52W Range3.21 - 18.33 Perf YTD-0.62%
Dividend Est.- P/FCF- EPS past 5Y-8.25% ROI-59.69% 52W High-55.92% Beta0.63
Dividend TTM- Quick Ratio4.42 Sales past 5Y0.00% Gross Margin-2251.94% 52W Low151.71% ATR (14)0.63
Dividend Ex-Date- Current Ratio4.63 EPS Y/Y TTM24.46% Oper. Margin-24549.63% RSI (14)30.88 Volatility8.05% 6.53%
Employees557 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin-23615.70% Recom1.31 Target Price25.18
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q15.53% Payout- Rel Volume0.98 Prev Close8.16
Sales Surprise-64.76% EPS Surprise1.01% Sales Q/Q- EarningsMay 09 AMC Avg Volume5.91M Price8.08
SMA20-10.66% SMA50-26.11% SMA200-8.21% Trades Volume5,778,942 Change-0.98%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated Goldman Buy $12
Sep-18-23Reiterated Barclays Overweight $40 → $18
May-30-23Upgrade Wells Fargo Equal Weight → Overweight $11 → $17
Mar-27-23Resumed Wells Fargo Equal Weight $11
Jan-27-23Upgrade Piper Sandler Neutral → Overweight $11 → $14
Dec-09-22Downgrade Goldman Buy → Neutral $20 → $6
Oct-31-22Initiated Guggenheim Neutral
Aug-18-22Resumed Wells Fargo Equal Weight $14
Jan-28-22Upgrade Stifel Hold → Buy $23 → $25
Dec-07-21Resumed Cowen Outperform
Jun-10-24 10:15AM
May-29-24 06:20AM
04:58AM
May-28-24 08:14AM
08:06AM
04:01PM Loading…
May-24-24 04:01PM
11:18AM
May-23-24 05:00PM
May-22-24 06:40AM
May-17-24 05:15PM
May-16-24 09:30AM
May-13-24 02:25PM
12:42PM
May-11-24 10:00AM
May-10-24 02:03PM
01:35PM Loading…
01:35PM
12:55PM
12:33PM
11:25AM
10:58AM
May-09-24 08:57PM
04:27PM
04:23PM
04:01PM
May-06-24 09:56AM
May-01-24 06:01AM
Apr-30-24 06:01AM
Apr-28-24 02:44PM
Apr-27-24 07:00AM
Apr-25-24 10:30AM
09:20AM Loading…
09:20AM
Apr-24-24 04:01PM
Apr-21-24 05:08AM
Apr-19-24 05:15PM
Apr-17-24 09:45AM
Apr-08-24 01:51PM
Apr-05-24 05:03AM
Mar-29-24 11:30AM
Mar-26-24 04:11AM
Mar-23-24 09:00AM
Mar-22-24 05:30PM
Mar-18-24 08:01PM
02:00AM
Mar-15-24 08:18AM
Mar-07-24 06:01AM
Mar-06-24 04:42AM
Mar-05-24 01:00PM
Mar-04-24 06:30AM
Mar-02-24 06:50AM
Mar-01-24 05:00PM
Feb-29-24 05:47PM
12:17PM
10:37AM
09:44AM
05:51AM
Feb-28-24 05:35PM
04:42PM
04:35PM
04:01PM
Feb-27-24 08:52AM
Feb-26-24 05:39AM
Feb-25-24 08:07AM
05:01AM
Feb-23-24 06:14AM
Feb-22-24 08:45AM
04:00AM
Feb-20-24 03:38PM
11:02AM
08:00AM
06:30AM
Feb-19-24 08:36AM
Feb-16-24 05:30PM
04:04PM
03:38PM
03:35PM
03:19PM
Feb-12-24 07:14AM
Feb-08-24 07:27AM
Feb-07-24 05:10AM
Feb-05-24 05:25AM
Feb-04-24 06:27AM
Jan-19-24 05:15PM
Jan-15-24 12:27PM
Jan-08-24 05:31AM
Dec-28-23 05:59PM
11:13AM
08:01AM
Dec-27-23 05:26PM
02:02PM
12:21PM
12:21PM
11:21AM
10:41AM
09:57AM
07:06AM
07:00AM
Dec-22-23 05:15PM
Dec-18-23 02:58PM
Dec-12-23 08:45AM
05:29AM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJun 03 '24Option Exercise0.003,906046,468Jun 05 08:07 PM
BILINSKY IGORChief Operating OfficerJun 03 '24Option Exercise0.003,516041,542Jun 05 08:05 PM
Vogt Frederick GInterim CEO & General CounselJun 03 '24Option Exercise0.0010,4170151,751Jun 05 08:04 PM
Vogt Frederick GInterim CEO & General CounselApr 15 '24Option Exercise0.0020,8340150,185Apr 17 07:08 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerApr 15 '24Option Exercise0.002,812043,989Apr 17 07:07 PM
BILINSKY IGORChief Operating OfficerApr 15 '24Option Exercise0.002,812039,453Apr 17 07:07 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerMar 04 '24Option Exercise0.0015,623049,230Mar 06 06:20 PM
Vogt Frederick GInterim CEO & General CounselMar 04 '24Option Exercise0.0041,6620140,800Mar 06 06:19 PM
Rothbaum Wayne P.DirectorFeb 20 '24Buy9.155,000,00045,750,00028,067,333Feb 20 04:11 PM
MCPEAK MERRILL ADirectorFeb 20 '24Buy9.15250,0002,287,500320,150Feb 20 07:52 PM
Dukes Iain D.DirectorFeb 20 '24Buy9.1532,000292,80054,000Feb 20 04:21 PM
Vogt Frederick GInterim CEO & General CounselJan 16 '24Option Exercise0.0020,8340105,668Jan 18 06:09 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 16 '24Option Exercise0.002,813035,184Jan 18 06:09 PM
BILINSKY IGORChief Operating OfficerJan 16 '24Option Exercise0.002,813031,444Jan 18 06:07 PM
Vogt Frederick GInterim CEO & General CounselOct 16 '23Option Exercise0.0020,835093,685Oct 18 08:05 PM
BILINSKY IGORChief Operating OfficerOct 16 '23Option Exercise0.002,813030,026Oct 18 08:04 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerOct 16 '23Option Exercise0.002,813033,766Oct 18 08:03 PM
MCPEAK MERRILL ADirectorSep 18 '23Buy5.5610,00055,600248,633Sep 19 04:30 PM
Rothbaum Wayne P.DirectorSep 15 '23Buy5.305,000,00026,500,00023,067,333Sep 15 06:12 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJul 14 '23Option Exercise0.002,813032,348Jul 17 06:22 PM
Vogt Frederick GInterim CEO & General CounselJul 14 '23Option Exercise0.0020,834081,701Jul 17 06:22 PM
BILINSKY IGORChief Operating OfficerJul 14 '23Option Exercise0.002,813028,608Jul 17 06:21 PM